Vanda Pharmaceuticals Inc.
VNDA
$5.24
-$0.10-1.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -2.30% | -9.61% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.30% | -9.61% | |||
| Cost of Revenue | 12.69% | -17.58% | |||
| Gross Profit | -3.27% | -9.04% | |||
| SG&A Expenses | 5.09% | 8.55% | |||
| Depreciation & Amortization | 0.00% | 13.41% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.16% | 4.48% | |||
| Operating Income | -27.05% | -24.46% | |||
| Income Before Tax | -28.83% | -27.42% | |||
| Income Tax Expenses | -9.79% | -99.86% | |||
| Earnings from Continuing Operations | -28.71% | 65.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -28.71% | 65.60% | |||
| EBIT | -27.05% | -24.46% | |||
| EBITDA | -28.34% | -25.24% | |||
| EPS Basic | -27.08% | 65.81% | |||
| Normalized Basic EPS | -27.19% | -20.16% | |||
| EPS Diluted | -26.83% | 65.68% | |||
| Normalized Diluted EPS | -27.19% | -20.16% | |||
| Average Basic Shares Outstanding | 1.29% | 0.61% | |||
| Average Diluted Shares Outstanding | 1.29% | 0.61% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||